Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer

World Journal of Oncology- Canada

doi 10.14740/wjon1193

Full Text

Abstract

Available in

Categories

Cancer Research

Date

January 1, 2019

Authors

Publisher

Elmer Press, Inc.

Related search

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi

English

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

Clinical Cancer Research

Cancer Research

English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer Research

English

Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Cancer Research

English

Is Smoking History the Truly Best Biomarker for Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer?

Cancer Research

English

Beyond Chemotherapy: Emerging Biomarkers and Therapies as Small Cell Lung Cancer Enters the Immune Checkpoint Era

Cancer Research

English

Prognostic Significance of Immune Cells in Non-Small Cell Lung Cancer: Meta-Analysis

English

Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non–Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Current Treatment Options in Oncology

English